Docetaxel in Non Small Cell Lung Cancer (NSCLC)

• Status: Completed
• Trial end date: 1969-12-31

Summary

Primary objective:

• To classify the 2 study groups, according to the tumoral response.

Secondary objectives:

• To evaluate the percentage of focused control per year.

• To calculate the time until progression.

• To evaluate the safety profile.

• Phase: Phase 2

Details

• Lead Sponsor: Sanofi
• Treatments: Carboplatin; Docetaxel; Gemcitabine